Micafungina Accord (Micafungin)

Micafungin blocks the fungal enzyme β‑1,3‑D‑glucan synthase, preventing the synthesis of 1,3‑β‑D‑glucan, an essential component of the fungal cell wall. This disruption weakens the wall, causing osmotic instability and cell death while sparing human cells.

The dose of Micafungina Accord is determined by the prescribing clinician based on the specific infection, patient weight, renal and hepatic function, and the therapeutic goal. No fixed regimen is provided here.

Safety data for micafungin in pregnancy and lactation are limited. The product should be used only if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by the treating physician.

To order Micafungina Accord, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required) and import documentation.

Micafungina Accord belongs to the echinocandin class, which targets the fungal cell wall, unlike azoles that inhibit ergosterol synthesis or polyenes that bind membrane sterols. Echinocandins generally have a favorable safety profile and are effective against many Candida species, including some azole‑resistant strains.

Micafungina Accord should be stored at 2‑8 °C (refrigerated). Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution. Once prepared for infusion, use according to aseptic technique and discard any unused portion after the recommended time.

Micafungina Accord is supplied as an intravenous solution and is administered by slow infusion into a vein under the supervision of a qualified healthcare professional. The infusion rate and duration are set by the prescriber based on the clinical indication and patient condition.

Serious risks include hypersensitivity reactions such as anaphylaxis, significant hepatotoxicity manifested by marked liver enzyme elevations or liver failure, and severe infusion‑related events like hypotension or bronchospasm. Prompt recognition and management of these events are essential.

Patients with a known hypersensitivity to micafungin or any component of the formulation should not receive Micafungina Accord. Caution is also advised for individuals with severe hepatic impairment, uncontrolled renal failure, or those receiving interacting medications that could increase toxicity.